Zai Lab

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zai Lab and other ETFs, options, and stocks.

About ZLAB

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. 

CEO
Ying Du
CEOYing Du
Employees
1,784
Employees1,784
Headquarters
Shanghai, Shanghai
HeadquartersShanghai, Shanghai
Founded
2014
Founded2014
Employees
1,784
Employees1,784

ZLAB Key Statistics

Market cap
2.19B
Market cap2.19B
Price-Earnings ratio
-12.15
Price-Earnings ratio-12.15
Dividend yield
Dividend yield
Average volume
755.52K
Average volume755.52K
High today
$19.80
High today$19.80
Low today
$19.02
Low today$19.02
Open price
$19.18
Open price$19.18
Volume
720.61K
Volume720.61K
52 Week high
$44.34
52 Week high$44.34
52 Week low
$15.96
52 Week low$15.96

ZLAB News

Simply Wall St 2d
How Investors Are Reacting To Zai Lab Narrowing Losses Amid Rising Q4 2025 Revenue

Zai Lab Limited recently reported past fourth-quarter 2025 results, with revenue rising to US$127.6 million from US$109.07 million and net loss narrowing to US$...

How Investors Are Reacting To Zai Lab Narrowing Losses Amid Rising Q4 2025 Revenue

Analyst ratings

87%

of 15 ratings
Buy
86.7%
Hold
13.3%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.